Loading…
Boston Scientific has agreed to acquire Apollo Endosurgery for $10 per share, an enterprise value of approximately $615 million, to expand its endoluminal surgery portfolio.
“Boston Scientific today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.”news.bostonscientific.com
Summarized from public sources; check the original articles before acting on it.